

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00858)

PROFIT WARNING

This announcement is made by Extrawell Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended 31 March 2026 (the “**Management Accounts**”), the Group expects to record a loss of at least HK\$950 million, as compared to a profit for the year ended 31 March 2025. The expected turnaround from profit to loss was primarily attributable to certain non-cash items, including (i) an unrealised loss ranging from about HK\$800 million to 850 million recognised on the Group’s investments in convertible bonds issued by Starcoin Group Limited whose shares were suspended from trading on the Stock Exchange from 6 May 2026, while a gain arising from fair value change of the same item was recorded in the corresponding period last year; and (ii) provision for impairment loss on the Group’s interest in an associate and loan receivables from the associate of about HK\$140 million in aggregate. During the year ended 31 March 2026, the Group’s operating segments have maintained a steady performance.

The Company is still in the process of preparing the annual results of the Group for the year ended 31 March 2026, the information as set out above is only based on the preliminary assessment by the Board on the information currently available to it, including the Management Accounts, which have not been finalised and are subject to audit or further review by the Company’s auditor. The annual results of the Group for the year ended 31 March 2026 are expected to be published before the end of June 2026.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Chairman

Hong Kong, 23 June 2026

As at the date of this announcement, the executive directors are Dr. Xie Yi, Dr. Guo Yi, Mr. Cheng Yong, Dr. Lou Yi and Ms. Wong Sau Kuen, and the independent non-executive directors are Ms. Jin Song, Dr. Zeng Li and Ms. Yang Xiaorong.

** For identification purpose only*